Laurie Glimcher, Dana-Farber president and CEO (Getty Images)
January 15, 2021 07:38 AM ESTUpdated 11:47 AM
Financing

With its rank-and-file churn­ing out star­tups, Dana-Far­ber launch­es ven­ture fund to cap­i­tal­ize on that suc­cess

Nicole DeFeudis

Editor

The pace of in­no­va­tion at the Dana-Far­ber Can­cer In­sti­tute in re­cent years has seen a wave of star­tups launch with IP or lead­er­ship sourced from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times